
zzso the value added by economic evaluations of clinical trials and the interaction of clinical, humanistic and economic end points, the zzso zzso Oncology Group zzso has developed an Outcomes Model that guides the comprehensive assessment of this zzso of end zzso This paper will focus on the economic component of the zzso The Economic Impact Committee was founded in 1994 to study the economic impact of clinical trials of cancer zzso A steep learning curve zzso with considerable time initially spent understanding the methodology of economic zzso Since then, economic analyses have been performed on zzso clinical trials involving treatments for patients with zzso cell lung cancer, zzso head and neck cancer and prostate zzso As the care of cancer patients zzso with time, so has the economic analyses performed by the Economic Impact zzso This paper documents the evolution of the zzso analyses of zzso from performing average zzso analysis to more technically sophisticated zzso Carlo simulation of zzso models, to incorporating prospective economic analyses as an initial end zzso Briefly, results indicated that, accounting for zzso survival, concurrent chemotherapy and radiation for the treatment of zzso cell lung cancer, more aggressive radiation zzso schedules for head and neck cancer and the addition of hormone therapy to radiation for prostate cancer are within the range of economically acceptable zzso The zzso economic analyses have provided information that can further inform clinicians and policy makers of the value added of new or improved zzso 

